CBD should not be scheduled within international drug control conventions, according to the latest meeting of the World Health Organization (WHO)’s Expert Committee on Drug Dependence (ECDD).

The 40th meeting of the ECDD focused on a review of cannabis and its component substances. During a critical review of evidence it established that CBD did not have psychoactive properties, and presented no potential for abuse or dependence.

The CBD investigation found that CBD did not appear to create THC-like effects and thus “generally the effects of CBD do not indicate the likelihood for abuse”.

“In a randomized, double-blind study using cannabis smokers, CBD administered by itself up to 800 mg produced no significant psychoactive, cardiovascular or other effects and was without abuse-related indicators in a variety of tests,” it said.

Read full article
I'm already a subscriber

Freddie Dawson

Managing editor, news
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the ECigIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization